Added Value of Vein of Marshal Ethanol Infusion Compared to Superior Vena Cava Isolation Alone in Patients Undergoing Repeat Ablation for Recurrent Paroxysmal Atrial Fibrillation Despite Durable PV Isolation

Last updated: August 2, 2022
Sponsor: AZ Sint-Jan AV
Overall Status: Active - Recruiting

Phase

N/A

Condition

Cardiac Disease

Chest Pain

Arrhythmia

Treatment

N/A

Clinical Study ID

NCT04529785
2700
  • Ages > 18
  • All Genders

Study Summary

The superior vena cava (SVC) is one of the most common non pulmonary vein (PV)-triggers for atrial tachyarrhythmias. SVC electrical isolation can be reached by circular radiofrequency (RF)-ablation under close monitoring of the phrenic nerve. However, adding substrate modification and vein of Marshal (VoM) ethanol infusion to the ablation procedure might substantially improve long-term outcomes.

The aim of this study is to evaluate the recurrence rate 1 year after the index ablation in patients undergoing a redo ablation for recurrent paroxysmal atrial fibrillation (PAF) despite durable pulmonary vein isolation (PVI) with either SVC isolation alone or with substrate modification including vein of Marshal ethanolisation in addition to SVC isolation alone

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Patients older than 18 years
  • Patients scheduled for a repeat ablation of PAF after a previous PVI
  • Confirmation of lasting pulmonary vein isolation at the time of randomization

Exclusion

Exclusion Criteria:

  • Patients with persistent atrial fibrillation
  • Previous ablation with isolation of the SVC, roofline, mitral line or previous vein ofMarshal ethanol infusion
  • Left atrial thrombus. Left atrial appendage thrombus can be determined bypreprocedural imaging: CT, transesophageal echocardiography or MRI.
  • Left ventricular ejection fraction <35%.
  • Cardiac surgery within the previous 90 days.
  • Expecting cardiac transplantation or other cardiac surgery within 180 days.
  • Coronary percutaneous transluminal coronary angioplasty/stenting within the previous 90 days or myocardial infarction within the previous 60 days.
  • Documented history of a thromboembolic event within the previous 90 days.
  • Diagnosed atrial myxoma.
  • Significant restrictive, constrictive, or chronic obstructive pulmonary disease withchronic symptoms.
  • Significant congenital anomaly or medical problem that in the opinion of theinvestigator would preclude enrollment
  • Women who are pregnant or who plan to become pregnant during the study.
  • Acute illness or active infection at time of index procedure
  • Advanced renal insufficiency
  • Unstable angina.
  • History of blood clotting or bleeding abnormalities.
  • Contraindication to anticoagulation.
  • Life expectancy less than 1 year.
  • Presence of a condition that precludes vascular access.
  • International Normalized Ratio greater than 3.5 within 24 hours of procedure - forpatients taking warfarin.
  • Patient cannot be removed from antiarrhythmic drugs for reasons other than AF.
  • Unwilling or unable to provide informed consent.

Study Design

Total Participants: 100
Study Start date:
September 11, 2020
Estimated Completion Date:
August 31, 2023

Connect with a study center

  • AZ Sint-Jan Brugge-Oostende AV

    Brugge, Please Select 8000
    Belgium

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.